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loss of DNA methylation in chronic rat epilepsy. Aber-
rant methylation patterns were inversely correlated with 
gene expression changes using mrNA sequencing from 
same animals and tissue specimens. Administration of 
a ketogenic, high-fat, low-carbohydrate diet attenuated 
seizure progression and ameliorated DNA methylation 
mediated changes in gene expression. This is the first 
report of unsupervised clustering of an epigenetic mark 
being used in epilepsy research to separate epileptic from 
non-epileptic animals as well as from animals receiving 
anti-convulsive dietary treatment. We further discuss the 
potential impact of epigenetic changes as a pathogenic 
mechanism of epileptogenesis.
Keywords epilepsy · Hippocampus · epigenetic · DNA 
methylation · Massive parallel sequencing · Ketogenic diet
Abstract epilepsy is a frequent neurological disor-
der, although onset and progression of seizures remain 
difficult to predict in affected patients, irrespective of 
their epileptogenic condition. Previous studies in animal 
models as well as human epileptic brain tissue revealed 
a remarkably diverse pattern of gene expression impli-
cating epigenetic changes to contribute to disease pro-
gression. Here we mapped for the first time global DNA 
methylation patterns in chronic epileptic rats and con-
trols. Using methyl-Cpg capture associated with mas-
sive parallel sequencing (Methyl-Seq) we report the 
genomic methylation signature of the chronic epileptic 
state. We observed a predominant increase, rather than 
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Introduction
Approximately 0.5–1 % of people suffers from epilepsy. 
One frequent epileptic syndrome is associated with drug-
resistant temporal lobe seizures and hippocampal neu-
rodegeneration, i.e., temporal lobe epilepsy with hip-
pocampal sclerosis (Tle-HS) [9]. Onset with an initial 
precipitating injury including trauma, inflammation, 
or prolonged acute symptomatic seizures is most char-
acteristic, followed by a clinically silent latency period 
before progression of spontaneous recurrent seizures 
[7, 58]. This pathogenic time course can be recapitu-
lated in experimental animal models of Tle, although 
specific disease mechanisms remain poorly understood. 
Array-based profiling studies have detected aberrant gene 
expression patterns. Several genes implicated in epilepsy 
have been identified and are thought to participate in 
inflammation and stress, synaptic transmission and sig-
nal transduction, ion transport, cell metabolism as well as 
synaptic plasticity [4, 16, 22, 26, 45]. We recently hypoth-
esized that a common regulatory trait for these abundant 
and long-lasting changes in gene expression relates to 
epigenetic changes such as genomic DNA methylation 
[34, 35] as well as specific chromatin changes, includ-
ing histone tail modification. recent experimental studies 
provide some evidence for aberrant epigenetic signatures 
induced by seizures. For example, alterations in histone 
tail modifications have been reported for histones H3 and 
H4 [28, 30, 69, 73] as well as phosphorylation of histone 
variant H2A.X [14]. Furthermore, the neuron restric-
tive silencing factor (Nrsf), which regulates neuronal 
gene expression and recruits DNA methyltransferases 
(Dnmts) as well as histone deacetylases (Hdacs), is 
involved in seizure development and progression [21, 44, 
51]. Altered microrNA expression [31] as well as DNA 
methylation patterns are also observed in rodent epilepsy 
models [53]. Our group was the first to show that aber-
rant DNA methylation of the reelin promoter associated 
with granule cell dispersion in human Tle [36]. Fur-
thermore, increased DNMT expression was observed in 
temporal neocortex samples obtained from Tle patients 
[79]. The experimental results of these studies implicate 
aberrant DNA methylation in the late, chronic and drug-
resistant stage of the disease.
Herein we used a massive parallel sequencing approach 
to examine persistent changes in genomic Cpg methyla-
tion correlated with gene expression in a chronic rat Tle 
model. Since dietary intake and nutrition are implicated 
in modifying epigenetic patterns [18], we examined the 
ketogenic diet (KD) in our model of chronic rat epilepsy. 
The high-fat, low-carbohydrate ketogenic diet is well rec-
ognized as anti-epileptic therapy with moderate success in 
man and experimental animal models [33, 38, 50, 54]. In 
this study, we demonstrate that early administration of an 
anti-convulsive ketogenic diet is associated with gene regu-
lating DNA methylation changes in rat Tle.
Materials and methods
Animal model: surgery, induction of status epilepticus 
and video-eeg recording
The experimental study was approved by the local animal 
care and use committee in accordance with the european 
Communities Council Directive (54-2532.1-23/09, Direc-
tive 2010/63/eU). Male Wistar rats weighting 300–350 g 
(Charles-river, germany; n = 14) were kept in individual 
cages under controlled environmental conditions (12 h 
dark/light cycles, 20–23 °C and 50 % relative humid-
ity) with drinking and feeding ad libitum. Animals were 
either fed a standard or ketogenic diet (KD, 4:1 ratio of fat 
over protein and carbohydrates, specifically designed for 
rodents and distributed by Altromin, lage, germany; data 
sheet access via http://www.altromin.de/de/upload/media/
specs/sonder/30009.pdf) and weekly controlled for body 
weight (Supplement Fig. 1a).
representative animals were assigned to continuous 
video-electroencephalography monitoring (veeg; n = 5; 
DSI, St. Paul, MN, USA). electrodes were implanted 
before seizure induction. rats were deeply anesthetized 
with an intraperitoneal injection of a ketamine (57 mg/
kg) and xylazine (9 mg/kg) mixture and placed in a stere-
otaxic apparatus (Bilaney Consultants, Düsseldorf, ger-
many). The skull was exposed and two holes were drilled 
(2 mm lateral to the sagittal suture and 5 mm anterior to 
the lambda suture, 1 mm diameter) to insert stainless 
steel screws (1 mm diameter, DIN84, Hummer und riess, 
Nuremberg, germany) passing the bone and touching but 
not penetrating the dura. Screws were connected with poly-
imide coated stainless steel lead wire, serving as eeg elec-
trodes. Afterwards, both screws were glued together with 
lead wires and surrounding bone using dental acrylic. The 
transmitter (F40-eeT, DSI, St. Paul, MN, USA) was placed 
into a subcutaneous pocket along the animal’s dorsal flank. 
All animals had time to recover for 1 week before further 
procedures. There were no differences in baseline eeg 
between animals before further treatment.
To induce status epilepticus (Se), animals were injected 
with a single high dose of the muscarinic receptor agonist 
pilocarpine (PIlO; 340 mg/kg, i.p.; Sigma-Aldrich, Stein-
heim, germany). Peripheral cholinergic effects were mini-
mized by administration of methyl scopolamine (1 mg/kg, 
s.c.; 30 min before injection of pilocarpine; TCI europe 
NV, Zwijndrecht, Belgium). Animals that experienced 
no Se within 45 min after first pilocarpine administration 
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were treated for a second time with half the application 
dosis (175 mg/kg, i.p.). After 60 min Se duration, ani-
mals received administration of diazepam (8 mg/kg, i.m.; 
Sigma-Aldrich). One hour following diazepam treatment 
glucose depots (2 × 5 ml) were subcutaneously injected to 
help animals to recover. Age matched control rats (CTrl; 
n = 5) received methyl scopolamine and saline (0.9 % 
NaCl; Sigma-Aldrich) injections only.
Behavioral seizures were scaled from 1 to 5 according 
to racine [61]. Se was defined as minimum three racine 
“class 5” behavioral seizures within 10 min and was identi-
fied, where applicable, from eeg recordings by high-ampli-
tude and -frequency discharges. All rats were continuously 
monitored (video or veeg, 24 h/7 days) following pilo-
carpine injections. The observation period lasted 84 days. 
Available eegs (PIlO n = 3/4 and PIlO + KD n = 2/5) 
were automatically screened for spontaneous seizure activ-
ity using the NeuroScore software (DSI). An eeg seizure 
was defined as a period of consistent, repetitive changes in 
amplitude and frequency of electrical activity that persisted 
for more than 10 s (Supplement Fig. 1c). Video images were 
used to confirm a clinical seizure where eeg abnormalities 
were detected. Behavioural seizures were further evaluated 
for the following parameters: latency to the appearance of 
first spontaneous seizure after Se in days; seizure severity 
according to racine’s scale; seizure duration in seconds; 
seizure frequency defined as the total number of detected 
seizures per week and life time seizures.
Neuropathological evaluation of our rat Tle model was 
performed in video-monitored reference cohorts (CTrl, 
PIlO and PIlO + KD; n = 3 each) treated as described 
above, but terminated 4 weeks following Se or sham injec-
tion. A detailed description of method and results is pro-
vided in the legend to Supplement Fig. 2.
Tissue preparation
For tissue preparation ether anesthetized animals were 
decapitated, the sculls opened and overlaying cortex 
removed for preparation of dorsal hippocampus. Five-mm-
thick hippocampal slices were prepared along the septo-
temporal axis and collected in icecold PBS, thereby, remov-
ing blood contamination. Hippocampi were snap frozen in 
liquid nitrogen and stored at −80 °C until further use. each 
probe was individually processed and not pooled with other 
samples. For downstream applications hippocampus was 
homogenized in ice cold 1× PBS and divided into equal 
volumes for DNA and rNA extraction.
DNA methylation profiling
Ten mg rat hippocampal tissue was used for genomic DNA 
extraction using the DNeasy Blood and Tissue Kit (Qiagen, 
Hilden, germany) according to the manufacturer’s instruc-
tions. Massive parallel sequencing of enriched methyl-
ated DNA was performed as described previously [57]. 
Briefly, 500 ng of rat hippocampal DNA from each animal 
(n = 14) was fragmented to a median size of 200–300 bp 
and subjected to methylated DNA capture according to the 
MethylMiner protocol (Invitrogen, Darmstadt, germany), 
exclusively enabling capture of methylated double stranded 
DNA. Fragmented and enriched DNA was eluted at high 
salt concentrations (2 M NaCl). Ten ng of enriched DNA 
was used in library preparation using the NeBNext DNA 
library Prep reagent Set for Illumina (New england Bio-
labs, Frankfurt/Main, germany). Quality of sequencing 
libraries was assayed using the Shimadzu MultiNA capil-
lary electrophoresis system (Shimadzu, Kyoto, Japan). 
libraries were sequenced at a concentration of 10 pM on 
the Illumina genome Analyzer IIx (Illumina, San Diego, 
CA, USA) with a 36 bp single read length. Image analysis 
and base-calling were performed with OlBv1.8 software. 
Sequenced tags were aligned to the rat genome rN4 using 
BWA (version 0.5.9) with default alignment parameters 
[43]. Profiles of DNA methylation were compared between 
all pairwise combinations of samples using the MACS peak 
calling software (version 1.4.0 rc2) with a fixed shift size of 
75 bp and a significance cut-off of 10e-05 [78]. genomic 
regions showing different methylation patterns between 
pairs of samples were merged using Bedtools [59]. Dupli-
cate reads which aligned to the same location in a given 
sample were removed from further analysis. The numbers 
of read tags aligning to each region were summarized using 
a custom python script producing a matrix of counts (tags 
per region per sample). The regions were non-differentially 
filtered for regions, where the sum of tag counts was below 
the 50th centile. These count data were tested for differen-
tial tag abundance using Bayesian shrinkage of a negative 
binomial model implemented in edger [64], and normal-
ized using trimmed mean normalization [65]. An adjusted 
p value was calculated using the Benjamini–Hochberg false 
discovery rate (FDr) [6]. Filtered gene lists meeting our 
significance criteria were submitted to pathway analysis 
using resources supplied by the database for annotation, 
visualization and integrated discovery (DAVID) [27].
gene expression profiling
Ten mg rat hippocampal tissue was used for total rNA 
extraction using the Trizol method, followed by DNAse 
digestion. rNA quality was verified on the Shimadzu 
MultiNA capillary electrophoresis system (Shimadzu). 
Following Dynabead Oligo(dT) enrichment (Invitrogen), 
mrNA was prepared into sequence ready libraries with the 
NeBNext mrNA library Prep reagent Set for Illumina 
(New england Biolabs). These samples were sequenced 
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as above. Sequenced tags were aligned to the rat genome 
rN4 using BWA (version 0.5.9) using default alignment 
parameters [43]. The numbers of read tags aligning to each 
gene were extracted using a custom python script produc-
ing a matrix of counts with regions based on the ensembl 
transcript annotation (version 66). genes were non-differ-
entially filtered for tag counts sums below the 30th centile. 
This count data was tested for differential tag abundance 
using Bayesian shrinkage of a negative binomial model 
implemented for in edger [64], and normalized using 
trimmed mean normalization [65]. An adjusted p value 
was calculated using the Benjamini–Hochberg false dis-
covery rate (FDr) [6].
gene set enrichment analysis of expression
rank scores for differential mrNA expression were cal-
culated as −log10 (p value) multiplied by the sign of the 
edger fold change so that upregulated genes had positive 
scores. These rank scores were used to test for correlations 
between mrNA expression and DNA methylation or ChIP-
Seq derived gene sets using the gSeA preranked method 
based on 1,000 gene set permutations [72]. Sets of differ-
entially methylated genes were derived by taking the dif-
ferentially methylated regions for each pairwise comparison 
between PIlO, and PIlO + KD with CTrl filtered for a p 
value <0.01 as determined by edger analysis, and separated 
into increased and decreased methylation. If any of these 
regions were co-located with either a gene body, TSS, pro-
moter (−3 kb from TSS), exon or intron they were assigned 
to that gene set, e.g., genes with an exon overlapping a region 
of increased methylation. The clustered transcription fac-
tor data set was downloaded (ftp://hgdownload.cse.ucsc.edu/
apache/htdocs/goldenpath/hg19/encodeDCC/apache/ 
htdocs/goldenpath/hg19/encodeDCC/wgencoderegTfbsClus
tered/) from the eNCODe profiling project [17]. A gene set 
for each transcription factor and cell line was generated by 
intersecting ChIP-Seq data with promoter annotation (−3 kb 
from TSS) using ensembl human genes (version 66), and 
assigning the intersecting gene promoters to that gene set. 
This analysis generated 425 gene sets, of which 403 (depend-
ing on gene set size) were used in gSeA. rat genes were 
mapped to Human genes using Homologene [1].
Quantification of gene expression
Total rNA was isolated using TrIzol (Invitrogen). 
genomic DNA contamination was removed by DNAse 
treatment (Qiagen). First-strand cDNA synthesis was per-
formed using the SuperScript II first strand synthesis Kit 
(Invitrogen) according to the manufacturer’s instructions. 
gene expression was analyzed on an ABI Prism 7500 Fast 
real-Time PCr Detection System (Applied Biosystems, 
Foster City, CA, USA). Forward and reverse primers were 
used at 100 nM together with Power SYBr green Master 
Mix (Applied Biosystems). reactions were incubated at 
95 °C for 10 min, followed by 40 cycles of 95 °C for 10 s 
and 60 °C for 30 s. For relative quantification (compara-
tive ΔΔCt method), gene expression was assessed at least 
in triplicates and normalized to internal reference Actb and 








DNA samples were processed for methylation-specific 
sequencing as described previously [25, 36]. Briefly, 
1 μg of genomic DNA was bisulfite converted using epi-
Tect DNA Bisulfite Kit (Qiagen), the region of interest 
pre-amplified, subcloned using topoisomerase TA vector 
(Invitrogen) and white colonies were selected and grown 
in lB broth. Plasmid was purified using gene Jet Plas-
mid Miniprep Kit (Fermentas, St. leon-rot, germany) 
and clones sequenced (commercial sequencing facility of 
gATC Biotech, Konstanz, germany). A minimum of six 
clones per subject with proven insertion of the PCr frag-
ment were analyzed. Sequences were quality controlled 
and aligned using the ClC sequence viewer v. 6.3 (ClC 
bio) and Quantitation tool for Methylation Analysis soft-
ware (rIKeN). Primers used for bisulfite sequencing were 
the following: Camkk2_BIS fw-TTTAgAggggATTT-
gAgTTTTT, rev-ATCCACCAATAAATCCAAATATTAC; 
Il10rb_BIS fw-gggTTAggATTgAgTTTgTAgAT, rev- 
TAAATAATAAAACCACCAAATTTATACTC.
Data access
Methyl-Seq and mrNA-Seq data were deposited in the 
NCBI gene expression Omnibus (geO; http://www.ncbi.n
lm.nih.gov/geo/query/acc.cgi?acc=gSe50080).
Results
Massive parallel sequencing identifies distinct genomic 
DNA methylation profiles in chronic rat epilepsy compared 
with controls
DNA methylation is a major epigenetic regulator of gene 
suppression [52], and has been implicated in experimental 
and human temporal lobe epilepsies [36, 53, 79]. However, 
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our knowledge on genomic methylation mediating gene 
expression changes in epilepsy is limited (1) to few spe-
cific gene loci comprehensively analyzed and (2) to the 
early stage of the disease (during or immediately follow-
ing Se). To examine the role of genomic DNA methylation 
in the chronic epileptic state, we used Methyl-capture and 
massive parallel sequencing (Methyl-Seq) of hippocampal 
tissue obtained from rats 12 weeks following pilocarpine 
induced status epilepticus (PIlO, n = 4) and compared 
these with respective healthy controls (CTrl, n = 5). 
We also examined gene expression changes using mrNA 
sequencing (mrNA-Seq) from the same tissue specimens 
to analyze the biological relevance of methylation changes 
(Fig. 1a).
Whole-genome DNA methylation profiling was per-
formed as previously described [12, 57]. A minimum of 
15 million short single reads (36 bp) was sequenced per 
sample, and an average 83 % of the short reads mapped 
unambiguously to the rat genome (rN4). The other 17 % of 
reads were likely to originate from repetitive DNA. Inter-
individual sample comparison revealed 310,070 regions 
covering 203,265,410 bp with variant methylation (~7.3 % 
of the rat genome). Pairwise comparison of global DNA 
methylation detected strong differences in methylation pat-
terns between all CTrl and PIlO samples. Hierarchical 
cluster analysis was used to assess and visualize underlying 
differences in DNA methylation profiles between samples 
and phenotypes. As shown in Fig. 1b, DNA methylation 
profiles readily discriminated samples into discrete groups 
according to the treatment.
To further examine changes in DNA methylation and its 
association with phenotype we mapped methylation pro-
files to the rat genome using Circos [39]. Increased (hyper-) 
and decreased (hypo-) methylation in PIlO samples were 
assigned to each chromosome and shown in red and green, 
respectively (Fig. 2a). We observed phenotype-specific 
regionalization of hyper- and hypomethylation events, 
which targeted the entire genome except chromosome X. 
Our analysis identified 2,573 individual loci that discrimi-
nate between chronic epileptic and control animals (cut-off 
p < 0.01). Thereof, 1,452 loci were hypermethylated and 
1,121 loci hypomethylated in chronic epilepsy samples 
compared to controls. These data imply that DNA meth-
ylation patterns of PIlO animals are indeed distinguishable 
from the reference CTrl animals.
Differential DNA methylation in chronic rat epilepsy  
is mainly confined to gene bodies
Because hypermethylation of Cpg-rich promoters is com-
monly regarded as a strong indicator of gene suppression 
in physiologic and pathologic conditions [77], we exam-
ined the extent of DNA methylation at different genomic 
regions. We compared the distribution of genomic meth-
ylation at Cpg islands (CgI), non-genic and genic regions 
(gene body including 5′ and 3′ untranslated regions), pro-
moters (3 kb upstream of transcription start), transcrip-
tional start sites (TSS) and exons as well as introns in the 
dissected hippocampi of chronic epileptic animals rela-
tive to controls. Differentially methylated regions were 
Fig. 1  Deep sequencing (Methyl-Seq) revealed increased genomic 
DNA methylation in chronic rat epilepsy. a Study design, b heat map 
displaying hierarchical clustering of samples and genomic regions 
according to differential methylation profiles (yellow methylation up, 
red methylation down). A specific DNA methylation signature char-
acterized chronic rat epilepsy. CTRL sham injected, healthy controls; 
PILO pilocarpine injected, chronic epileptic animals. Clustering was 
performed by taking the trimmed mean normalized values for dif-
ferential regions as defined by edger analysis with a p value <0.01. 
These values were normalized to the standard normal distribution 
before performing euclidean distance based hierarchical clustering 
on both regions and samples using the heatmap.2 function in the r 
package gplots
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normalized and expressed as log2 odds ratios of observed 
differences compared to non-differentially methylated 
genomic features. We report the mean frequency of meth-
ylation changes with upper and lower 95 % confidence 
intervals for the genomic features (Fig. 2b). We identified a 
significant increase in DNA methylation content in chronic 
epilepsy specimen, when comparing hyper- and hypometh-
ylation events at specific genomic features. Table 1 shows 
predominant increase in DNA methylation at CgIs and 
gene bodies, exons as well as introns (Fisher’s exact Test, 
p < 0.05). generally, DNA methylation changes were fre-
quently found at Cpg islands (CgI) as well as genic and 
non-genic regions. regarding non-genic sites, we did not 
so much observe differential methylation of gene promot-
ers (Fig. 2b). Instead, we detected changes more readily 
distal from coding regions of genes.
gene expression profiling in chronic epileptic rats
We have previously postulated DNA methylation changes 
as potential cause of aberrant gene expression in experi-
mental and human Tle [34, 35]. To test this hypothesis, 
we compared genomic methylation patterns with gene 
expression data derived from same hippocampal speci-
mens using mrNA-Seq (n = 3 per treatment group). gene 
expression profiling identified 1,502 genes that were dif-
ferentially expressed in chronic epileptic rats compared to 
healthy controls (cut-off p < 0.01; Fig. 3). gene annotation 
in DAVID [27] revealed biological functions implicated in 
pathomechanisms underlying chronic epilepsy, which was 
consistent with previous reports from animal and human 
studies using epileptic brain tissue. Kegg pathway analy-
sis of downregulated genes in chronic epileptic hippocampi 
(n = 517) showed enrichment for MAPK and calcium sign-
aling, axon guidance, long-term depression and potentia-
tion, whereas overexpressed genes (n = 985) were associ-
ated with pathways participating in chronic inflammation, 
immune response, and neurodegeneration (Table 2).
Furthermore, we observed a large number of seizure-
related genes [40] to be differentially expressed in PIlO 
animals, including voltage-gated calcium, potassium or 
sodium channels (Cacng2, Itpr1, Kcna1, Kcna2, Kcnq2, 
Scn4b, Scn8a), calcium pumps (Atp2a2), neurotransmit-
ter receptors (gabrd), g-protein-coupled receptors (gpr56) 
as well as components of the cytoskeleton (gfap), proteins 
implicated in cell adhesion (Pcdh19), transcription factors 
(Tgif1) and metabolic enzymes (Ndufa2, Npc2) shown in 
Table 3. We also identified genes, which have not been pre-
viously associated with brain function, seizure generation 
or epilepsy-related processes.
recent experimental results in human Tle detected 
altered expression of DNMT isoforms [79]. These enzymes 
are involved in the establishment or maintenance of 
genomic DNA methylation patterns [19, 55, 79]. Analysis 
of our mrNA-Seq data revealed no significant change in 
gene expression for the DNA methyltransferases Dnmt1, 
Dnmt3a and Dnmt3b in the PIlO cohort. But chromatin 
structure and function may not exclusively be regulated 
through DNA methylation. We report differential gene 
expression of other key epigenetic enzymes and down-
stream effector proteins implicated in histone acetylation 
and methylation, as well as micro rNA processing and 
Fig. 2  genomic distribution of DNA methylation changes (cut-off 
p < 0.01) in chronic rat epilepsy. a rat genome ideogram summariz-
ing hypermethylation (red) and hypomethylation events (green) in 
PIlO versus CTrl. DNA methylation targeted the entire genome 
with almost complete sparing of the X-chromosome (ChrX). b Fre-
quency of observed methylation changes compared to non-differ-
entially methylated regions [−log10 (p value) <0.25], with upper 
and lower 95 % confidence intervals for different genomic features. 
Hypermethylation relative to controls is shown in the left panel (red 
bars), whereas, hypomethylation relative to controls is shown in 
the right panel (green bars). DNA methylation events were mainly 
confined to CgIs, but did not frequently target promoters. CGI Cpg 
island, TSS transcriptional start site, O/E observed/expected ratio, 
5mC 5-methyl-cytosin. Asterisks indicate significance (p < 0.05 using 
Fisher’s exact test)
747Acta Neuropathol (2013) 126:741–756 
1 3
ATP-dependent chromatin remodeling (manual inspection 
and gO term analysis, cut-off p < 0.01, Table 4). These 
results suggest that different epigenetic pathways could be 
involved in the pathogenesis of epilepsy and maintenance 
of the chronic disease state.
DNA methylation is inversely correlated with gene 
expression in chronic epileptic rats
Next we determined whether DNA methylation changes 
targeted gene expression in our model of chronic epilepsy. 
A gene Set enrichment Analysis (gSeA) was performed 
[72] using the ranked mrNA results and sets of differen-
tially methylated genes as described above. In PIlO ani-
mals, differential DNA methylation targeted 1,180 specific 
gene loci (overlap ≥1 bp with annotated promoter, TSS or 
gene body). generally, these DNA methylation changes 
were not associated with alterations in gene expression 
(n = 930, 79 %). However, for 250 gene loci (21 %) a 
strong correlation between differential DNA methylation 
and gene expression was identified. DNA hypermethylation 
of gene bodies, introns as well as exons was clearly asso-
ciated with gene silencing in chronic rat epilepsy, but we 
did not find hypermethylation of gene promoters correlated 
with gene suppression (Fig. 4 upper panel, and Supplement 
Table 1). In contrast, decreased methylation was associ-
ated with increased gene expression and a feature of exons, 
introns, TSS and gene promoters (Fig. 4 lower panel, and 
Supplement Table 1).
To understand biological pathways targeted by altered 
gene expression patterns and DNA methylation, we per-
formed Functional Annotation Clustering using DAVID. 
This analysis identified enrichment of genes implicated in 
cytoskeleton organization, immune response and inflamma-
tion, neuronal development and differentiation, cell adhe-
sion, as well as cell projection. Furthermore, we observed 
changes in genes involved in calcium signaling, DNA bind-
ing and transcription, programmed cell death, and synaptic 
transmission (enrichment score for all clusters >1.5). Taken 
together, gSeA would support a biological relevance of 
DNA methylation changes in our experimental epilepsy 
model.
Validation of candidate genes in epilepsy
Next we sought to validate DNA methylation targeted 
gene expression. Bisulfite sequencing was used to verify 
differential methylation from Methyl-Seq in chronic rat 
epilepsy compared to healthy controls. To quantify dif-
ferences in Cpg methylation between PIlO and CTrl, 
Table 1  genomic features targeted by DNA methylation
Table shows statistics comparing ratio of the number of increased versus decreased methylated regions (cut-off p < 0.01) across genomic fea-
tures. p value calculated with Fisher’s exact test (p < 0.05 was considered significant)
CGI Cpg island, TSS transcriptional start site, OL number of loci overlapping feature (overlap ≥1 bp), NOL number of loci not overlapping fea-
ture, CI confidence interval
Feature Up_Ol Up_NOl Down_Ol Down_NOl log2 odds ratio lower CI Upper CI p value
CgI 148 1,304 17 1,104 2.881 2.142 3.708 9.7e-22
gene body 831 621 510 611 0.681 0.450 0.912 3.7e-09
Non-genic 692 760 651 470 −0.605 −0.836 −0.374 1.8e-07
Intron 783 669 489 632 0.597 0.366 0.828 2.3e-07
exon 438 1,014 255 866 0.553 0.289 0.818 2.5e-05
Promoter 108 1,344 69 1,052 0.293 −0.173 0.766 2.1e-01
TSS 53 1,399 31 1,090 0.413 −0.264 1.113 2.2e-01
Fig. 3  mrNA-Seq identified highly distinct gene expression sig-
natures in chronic rat epilepsy and controls. Heat map displaying 
hierarchical clustering of samples and genes according to differen-
tial expression profiles normalized to the standard normal distribu-
tion (yellow expression up, red expression down). Treatment groups 
can be clearly differentiated by their expression profiles. CTRL sham 
injected, healthy controls; PILO chronic epileptic animals. Cluster-
ing was performed by taking the trimmed mean normalized values 
for genes as defined by edger analysis with a p value <0.01. These 
values were normalized to the standard normal distribution before 
performing euclidean distance based hierarchical clustering on both 
regions and samples using the heatmap.2 function in the r package 
gplots
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Mann–Whitney U test was performed. Fisher’s exact Test 
was further calculated to analyze the independence of Cpg 
methylation between two treatment groups at a particular 
Cpg site. The schematic shown in Fig. 5 (middle panel) 
illustrates the gene and its chromosomal localization as well 
as the location of the amplicon examined using bisulfite 
sequencing. We confirmed the hypermethylation status 
of Camkk2 (Ca2+/Calmodulin-dependent protein kinase 
kinase 2, beta; rN4 genome assembly, chr12:34936408-
34936667; Mann–Whitney U test p = 1e − 07; Fig. 5a, 
left panel; Supplement Table 2a), a key enzyme in Ca2+ 
signaling involved in hippocampus-dependent long-term 
memory, and hypomethylation of the Il10rb locus (inter-
leukin 10 receptor, beta; rN4, chr11:31381431-31381722; 
Mann–Whitney U test p = 1e-06; Fig. 5b, left panel; 
Supplement Table 2b), an endogenous cytokine recep-
tor involved in anti-inflammation and neuroprotection, in 
chronic rat epilepsy compared to healthy controls.
We further validated gene expression changes identi-
fied by mrNA-Seq using qrT-PCr. Camkk2 gene expres-
sion was significantly reduced in PIlO animals (unpaired 
two-tailed t test, p = 6.0e-04; Fig. 5a, right panel) and 
consistent with increased gene methylation. Increased 
expression of Il10rb (unpaired two-tailed t test, p = 9.3e-
03; Fig. 5b, right panel) was inversely correlated with a 
hypomethylation phenotype in chronic rat epilepsy. These 
results confirm gene expression changes mediated by DNA 
methylation, as identified in our genome-wide sequencing 
Table 2  Functional enrichment of gO terms and Kegg pathways in chronic rat epilepsy gene expression
GO gene ontology, KEGG Kyoto encyclopedia of genes and genomes, count number of genes from our data set contributing to gO term and 
Kegg pathway enrichment, rno rattus Norvegicus
Term Count p value Term Count p value
gO terms
 gO: molecular function  gO: biological process
  gO: 0003779—actin binding 27 1.8e−04   gO: 0006955—immune response 50 1.8e−07
  gO: 0004714—transmembrane recep-
tor tyrosine kinase activity
10 1.1e−03   gO: 0043067—regulation of programmed 
cell death
63 4.3e−05
  gO: 0051015—actin filament binding 8 6.9e−03   gO: 0007610—behavior 44 5.2e−05
  gO: 0016563—transcription activator 
activity
25 1.1e−02   gO: 0016477—cell migration 31 6.7e−05
  gO: 0005272—sodium channel 
activity
6 1.3e−02   gO: 0007155—cell adhesion 46 9.6e−05
  gO: 0022890—inorganic cation trans-
membrane transporter activity
15 1.4e−02   gO: 0030100—regulation of endocytosis 11 1.3e−03
  gO: 0005216—ion channel activity 28 1.5e−02   gO: 0060627—regulation of vesicle-
mediated transport
15 2.8e−03
  gO: 0005261—cation channel activity 22 1.8e−02   gO: 0050804—regulation of synaptic 
transmission
19 3.6e−03
  gO: 0005262—calcium channel 
activity
9 2.3e−02   gO: 0048167—regulation of synaptic 
plasticity
12 4.1e−03
  gO: 0005244—voltage-gated ion 
channel activity
16 3.1e−02   gO: 0048666—neuron development 31 7.6e−03
Kegg pathways
 Downregulated genes  Upregulated genes
  rno04020: calcium signaling pathway 15 2.2e−05   rno04610: complement and coagulation 
cascades
14 1.4e−06
  rno04010: MAPK signaling pathway 17 1.2e−04   rno00190: oxidative phosphorylation 16 1.6e−04
  rno04360: axon guidance 9 4.9e−03   rno05012: Parkinson’s disease 15 7.8e−04
  rno04730: long-term depression 6 1.2e−02   rno04612: antigen processing and  
presentation
11 1.5e−03
  rno04720: long-term potentiation 6 1.3e−02   rno04650: natural killer cell mediated 
cytotoxicity
11 3.9e−03
  rno04912: gnrH signaling pathway 7 1.4e−02   rno05016: Huntington’s disease 15 1.1e−02
  rno04070: phosphatidylinositol signal-
ing system
6 1.5e−02   rno04514: cell adhesion molecules 
(CAMs)
12 2.2e−02
  rno04144: endocytosis 10 2.4e−02   rno05010: Alzheimer’s disease 14 3.2e−02
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approaches, using independent assays such as bisulfite 
sequencing and qrT-PCr, respectively.
Ketogenic diet ameliorates seizure-induced DNA 
methylation in chronic rat epilepsy
Next we explored whether anti-epileptic treatment could 
change DNA methylation mediated gene expression in our 
experimental animal model, because medically refractory 
epilepsies frequently respond to strict dietary regimens. 
Indeed, the ketogenic diet (KD), a high-fat, moderate pro-
tein diet with low carbohydrate content has been implicated 
in regulating gene expression by modifying chromatin 
structure [68]. To test our hypothesis that a ketogenic diet 
could alter DNA methylation mediated gene expression we 
fed a subset of animals with a non-calorie restricted KD 
(PIlO + KD) immediately following Se. KD treatment 
had no effect on Se as the initial precipitating injury. We 
tested ketosis as reliable parameter that the KD changed 
the animals’ metabolism 2 weeks after initial treatment 
using standard reagent strips for urine analysis, i.e., “keto-
sticks” (Bayer, leverkusen, germany; Supplement Fig. 2). 
To assess any effect of dietary treatment on clinical phe-
notype, behavioral seizures were continuously monitored 
Table 3  Differential gene expression of epilepsy-related genes
According to gene Cards, JaxMice Database and lemke et al. [40]
logFC log2 fold change, leading sign indicates direction of change (+, increase; −, decrease), FDR false discovery rate, BFNS benign familial 
neonatal seizures, GEFS+ generalized epilepsy with febrile seizures plus, IGE idiopathic generalized epilepsy, JME juvenile myoclonic epilepsy
gene ID gene name Seizure-related disorder ensembl transcript ID logFC p value FDr
Scn4b Sodium channel, voltage-
gated, type IV, beta
long QT syndrome; 
Jervell-lange Nielsen 
syndrome
eNSrNOT00000030152 −2.2 5.9e−13 5.3e−10
gfap glial fibrillary acidic protein Alexander disease eNSrNOT00000034401 1.7 1.2e−09 4.9e−07
Npc2 Niemann-Pick disease, type 
C2
Niemann-Pick disease eNSrNOT00000016076 1.2 9.6e−07 1.8e−04
Itpr1 Inositol 1,4,5-triphosphate 
receptor, type 1
Itpr1−/− with seizure phe-
notype; Spinocerebellar 
ataxia
eNSrNOT00000009288 −1.2 1.1e−06 2.0e−04
Pcdh19 Protocadherin 19 early infantile epileptic 
encephalopathy
eNSrNOT00000042335 −1.2 9.2e−06 1.2e−03
gabrd gamma-aminobutyric acid 
(gABA) A receptor, delta
geFS+; Ige; JMe eNSrNOT00000022246 −0.9 1.3e−04 8.9e−03
Kcna1 Potassium voltage-gated 
channel, shaker-related 
subfamily, member 1
episodic ataxia; partial 
epilepsy
eNSrNOT00000026731 −1.1 1.9e−04 1.1e−02
Tgif1 TgFB-induced factor home-
obox 1
Holoprosencephaly eNSrNOT00000021534 1.5 2.7e−04 1.5e−02
Cacng2 Calcium channel, voltage-
dependent, gamma  
subunit 2
Cacng2−/− with seizure 
phenotype; Absence epi-
lepsy; mental retardation
eNSrNOT00000008414 −0.9 1.5e−03 4.8e−02
Ndufa2 NADH dehydrogenase 
(ubiquinone) 1 alpha sub-
complex, 2
leigh syndrome eNSrNOT00000023811 0.9 1.7e−03 5.0e−02
Scn8a Sodium channel, voltage 
gated, type VIII, alpha 
subunit
Cerebellar atrophy, ataxia 
and mental retardation
eNSrNOT00000008160 −1.0 2.1e−03 5.8e−02
gpr56 g protein-coupled  
receptor 56
Polymicrogyria eNSrNOT00000020921 −0.8 2.4e−03 6.1e−02
Kcnq2 Potassium voltage-gated 
channel, KQT-like  
subfamily, member 2
BFNS; early infantile epi-
sodic encephalopathy
eNSrNOT00000016574 −1.0 2.5e−03 6.4e−02
Atp2a2 ATPase, Ca++ transport-
ing, cardiac muscle, slow 
twitch 2
Darier-White disease eNSrNOT00000067047 −0.9 3.4e−03 7.4e−02
Kcna2 Potassium voltage-gated 
channel, shaker-related 
subfamily, member 2
Kcna2−/− with seizure 
phenotype; episodic 
ataxia
eNSrNOT00000050149 −0.9 3.9e−03 7.9e−02
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during the entire study period of 12 weeks after Se. Com-
pared to Se-experienced animals fed a standard diet, KD 
administration did not result in differences regarding 
latency period or mean severity and duration of clinical 
seizures. A significant difference, however, was detected 
according to seizure frequency per week (paired two-tailed 
Table 4  epigenetic signature in gene expression
According to gO terms and manual inspection
logFC log2 fold change, leading sign indicates direction of change (+, increase; −, decrease), FDR false discovery rate, DNMT DNA methyl-
transferase, HAT Histone acetyltransferase, HMT Histone methyltransferase, miR microrNA, 5mC 5-methyl-cytosin
geneID gene name Function ensembl transcript ID logFC p value FDr
gadd45a growth arrest and DNA-dam-
age-inducible 45 alpha
DNA demethylation, base exci-
sion repair
eNSrNOT00000007698 1.42 2.2e−06 3.6e−04
Apobec1 Apolipoprotein B mrNA 
editing enzyme, catalytic 
polypeptide 1
DNA demethylation, cytidine 
deaminase, base excision 
repair
eNSrNOT00000020735 1.27 3.5e−04 1.7e−02
eif2c1 eukaryotic translation initia-
tion factor 2C, 1; argonaute 
1
mir pathway, inhibition of 
translation
eNSrNOT00000037728 −0.94 8.6e−04 3.4e−02
Ncoa1 Nuclear receptor coactivator 1 HAT activity towards H3 and 
H4, participates in chromatin 
remodeling and recruitment 
of general transcription factors
eNSrNOT00000005782 −0.89 1.0e−03 3.7e−02
ezh1 enhancer of zeste homolog 1 HMT activity, H3K27 specific eNSrNOT00000027640 −0.87 1.1e−03 3.8e−02
Zmynd8 Zinc finger, MYND-type 
containing 8
Chromatin remodeling factor eNSrNOT00000025932 −0.80 1.7e−03 5.0e−02
Mthfs 5, 10-methenyltetrahydrofolate 
synthetase
Folate metabolism and trans-
methylation pathway
eNSrNOT00000039850 1.14 3.9e−03 7.9e−02
Mll1 Myeloid/lymphoid or mixed-
lineage leukemia 1
HMT activity, H3K4 specific eNSrNOT00000020573 −0.87 5.3e−03 9.4e−02
Nrip1 Nuclear receptor interacting 
protein 1
Serves as a scaffold for both 
DNMT and HMT activities to 
inhibit gene transcription
eNSrNOT00000002152 −0.82 5.4e−03 9.5e−02
Cbx5 Chromobox 5 HP1 homolog, binding of 5mC eNSrNOT00000055289 0.72 5.5e−03 9.6e−02
Fig. 4  gene set enrichment analysis (gSeA) of methylated pro-
moters, TSS and gene bodies were performed against the rank of 
our mrNA-Seq data from same samples. gSeA was separately per-
formed for gene sets showing increased or decreased methylation in 
chronic rat epilepsy. A strong correlation (FDr < 0.25 was consid-
ered significant) was observed between gene body methylation and 
gene repression, and conversely, between loss of intragenic methyla-
tion and activated gene expression. Promoter hypermethylation was 
not associated with gene repression. FDR false discovery rate, T 
thousand, CTRL sham injected, healthy controls, PILO pilocarpine 
injected, chronic epileptic animals. Supplement Table 1 contains 
comprehensive gSeA statistics
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t test, p = 4.0e-04; mean ± SeM: PIlO = 24.5 ± 4.7, 
PIlO + KD = 6.9 ± 1.9) with a reduction in seizure bur-
den upon KD treatment and apparent delay in the chroni-
fication of the disease (Supplement Fig. 1b). recordings 
from subdural electrodes and limited sample numbers with 
veeg-monitoring did not allow meaningful quantifica-
tion of KD effects on eeg data, but comparison of racine 
stage 5 clinical seizures and baseline eeg provided no evi-
dence for treatment specific differences between PIlO and 
PIlO + KD (Supplement Fig. 1c).
We analyzed differential methylation in epileptic ani-
mals assigned to anti-epileptic dietary treatment. Pairwise 
analysis of PIlO + KD versus CTrl identified 1,785 
loci that were differentially methylated. Thereof, 1,003 
loci associated with hypermethylation and 782 regions 
with hypomethylation. Interestingly, the targeted genomic 
regions showed limited overlap with regions previously 
identified in our untreated epileptic PIlO animals (Fig. 6a, 
blue). In KD-treated animals we observed strong reduction 
in DNA methylation at gene bodies as well as intronic and 
exonic regions. These results clearly show that genomic 
DNA methylation patterns of CTrl and PIlO animals 
are distinguishable from the PIlO + KD group. All ani-
mals from the PIlO and PIlO + KD group experienced 
convulsive seizures within 48 h preceding their termination 
(unpaired two-tailed t test, p > 0.05), suggesting that differ-
ences in methylation between groups were not dependent 
on the time point of their last seizure.
gene expression profiling in KD-treated rats identified 
400 differentially regulated genes compared to over 1,500 
aberrantly expressed genes in PIlO (cut-off p < 0.01; 
Fig. 6b). gene expression again was inversely corre-
lated with genomic DNA methylation patterns (Supple-
ment Table 1). To determine whether expression changes 
were associated with the anti-seizure phenotype and not 
induced by the diet, we compared our mrNA-Seq data 
with a recently described gene expression profile (geO 
Data Set 954) derived from healthy, non-epileptic rats 
receiving a KD [10]. Consistent with our hypothesis that 
an anti-convulsive dietary treatment could alter DNA meth-
ylation mediated gene expression in rat epilepsy there was 
no correlation between the reference CTrl + KD and our 
PIlO + KD (data not shown).
Validation experiments of our candidate genes, Camkk2 
and Il10rb, provide additional evidence that the ketogenic 
diet may be useful to ameliorate aberrant seizure-associated 
DNA methylation (Mann–Whitney U test, pCamkk2 = 2.5e-
02 and pIl10rb = 2.1e-02; Fig. 6c) and concomitant gene 
expression (one-way ANOVA with Bonferroni post hoc 
test, pCamkk2 = 3.4e-03 and pIl10rb = 2.0e-02; Fig. 6d).
gene expression profiles reveal further regulatory 
pathways implicated in chronic epilepsy
gene expression is coordinated by complex regulatory 
mechanisms that involve transcription factor binding and 
chromatin modification including DNA methylation. To 
explore mechanisms that serve to regulate coordinated 
gene expression changes in chronic rat epilepsy we exam-
ined our mrNA-Seq data for changes consistent with 
Fig. 5  Left panel showing bisulfite sequencing results (Bis-Seq, 
n = 3). White dots represent unmethylated and black dots methylated 
Cpgs. Middle panel summarizing schematic gene structure with TSS 
(green arrow), chromosomal region and region covered in Bis-Seq. 
Right panel presenting gene expression data from rT-PCr (n = 5). 
C, CTRL control (white bar); P, PILO chronic epileptic animals 
(red bar). Asterisks indicate significance (unpaired two-tailed t test, 
p < 0.05). a Camkk2 showed hypermethylation and concomitant gene 
repression in PIlO versus CTrl. b Hypomethylation of the Il10rb 
locus and increased gene expression could be confirmed in PIlO ver-
sus CTrl
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transcription factor signaling using gSeA. We found that 
genes downregulated in our epilepsy model (PIlO and 
PIlO + KD) shared binding motifs for neuron restrictive 
silencing factor (Nrsf) and suppressor of zeste 12 (Suz12). 
The former is a major transcriptional regulator of neuronal 
gene expression that recruits Dnmts and Hdacs, and the 
latter is a central component of the Polycomb repressor 
complex 2 (Prc2). Downregulated genes from PIlO and 
PIlO + KD animals with Suz12/Prc2 binding capacity 
were generally hypomethylated, consistent with a recent 
study [24]. examination of upregulated genes in PIlO and 
PIlO + KD animals identified that nuclear factor kappa 
B (Nfkb), K(lysine) acetyltransferase 2 (Kat2a), zinc fin-
ger ZZ domain containing 3 (Zzz3), general transcription 
factor IIB (gtf2b) and p300 binding motifs were com-
monly shared. Nfkb is a rapidly acting primary transcrip-
tion factor that plays a key role in regulating inflamma-
tion and immune response also in epilepsy [74]. Kat2a, 
Zzz3 and p300 are distinguished transcriptional activators, 
which share histone acetyltransferase activity [70]. Taken 
together, our results indicate that important transcription 
factors, which serve to function in chromatin modifica-
tion, together with DNA methylation may participate in 
regulating common patterns of gene expression in chronic 
epilepsy.
Discussion
This is the first report describing genome-wide changes 
in DNA methylation in the chronic stage of rat Tle. Dis-
secting rat hippocampal tissue, mrNA sequencing identi-
fied deregulation of seizure- and epilepsy-related genes, 
metabolic and key epigenetic enzymes or regulators. DNA 
methylation was found to be inversely correlated with 
gene expression, and candidate genes were validated using 
bisulfite sequencing and real-time PCr. Ketogenic diet, a 
well recognized anti-epileptic treatment in children with 
severe, chronic epilepsy [13, 54], attenuated seizure bur-
den, delayed chronification of the disease and partially res-
cued the DNA methylation and corresponding gene expres-
sion phenotype.
DNA methylation not only regulates cell fate determina-
tion and maturation in the brain but also plays a role for the 
induction of activity-dependent synaptic plasticity, memory 
and cognition [20, 41, 42, 60]. The importance of epige-
netic tuning of higher order brain function is emphasized 
by a growing number of neurological diseases that associ-
ate with alterations in DNA methylation, including autism 
spectrum disorders, schizophrenia, Alzheimer’s disease, 
brain tumors, spinal muscular atrophy and, more recently, 
epilepsy [35]. So far, epigenetic gene regulation in epilep-
togenesis had only been investigated for individual candi-
date genes (e.g., reelin, BDNF, glur2) and/or focused on 
the very early stage of the disease, during or immediately 
following Se [36, 47, 53, 73]. Our present study is unique 
for its simultaneous DNA methylation and gene expression 
profiling, suggesting DNA methylation as potential molec-
ular pathomechanism in chronic epilepsy contributing to 
the deregulation of multiple genes.
Fig. 6  Comparison of differential DNA methylation and gene 
expression patterns in pilocarpine injected, epileptic animals receiv-
ing anti-convulsive ketogenic diet (PIlO + KD, blue) or no treat-
ment (PIlO, red). The KD treatment partially ameliorated molecu-
lar changes associated with chronic rat epilepsy. effects were more 
pronounced on a genomic scale than at certain loci of selected can-
didate genes. a Venn diagram displaying overlap in differential DNA 
methylation between PIlO and PIlO + KD compared to CTrl. 
KD-treated animals showed a distinct genomic methylation profile 
compared to untreated chronic rat epilepsy. Administration of the KD 
seemed to have rescued a majority of affected loci. b Venn diagram 
displaying overlap in differential gene expression between PIlO and 
PIlO + KD compared to CTrl. KD-treated animals showed a dis-
tinct gene expression pattern compared to untreated chronic rat epi-
lepsy. A majority of differentially expressed genes in PIlO were res-
cued upon KD treatment. genes exclusively expressed in PIlO + KD 
may have contributed to adverse side effects. c Bisulfite sequencing 
results. Camkk2 hypermethylation in PIlO animals was significantly 
reduced by KD treatment (Mann–Whitney U test, p < 0.05). Fur-
ther, hypomethylation of the Il10rb locus in PIlO was reversed in 
KD + PIlO. White dots represent unmethylated and black dots meth-
ylated Cpgs. d gene expression of Camkk2 and Il10rb in PIlO and 
PIlO + KD. KD treatment partially rescued Camkk2 gene expres-
sion, but had no significant effect on Il10rb. C, CTRL control (white 
bar); P, PILO chronic epileptic animals (red bar); KD, PILO + KD 
pilocarpine injected animals receiving anti-convulsive ketogenic die-
tary treatment (blue bar). Asterisks indicate significance (univariate 
one-way ANOVA followed by Bonferroni post hoc test, p < 0.05)
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We observed specific DNA methylation signatures, 
which readily discriminate chronic epileptic PIlO from 
reference CTrl and PIlO + KD animals using hierarchi-
cal cluster analysis. genome-wide unsupervised cluster-
ing of an epigenetic mark could distinguish epileptic from 
non-epileptic animals. We observed more frequent hyper-
methylation of genes in rats with chronic epilepsy. Indeed, 
changes in DNA methylation were predominantly located 
at CgIs within gene bodies, and generally did not target 
gene promoters. A similar pattern of gene body methyla-
tion was recently described in the healthy rat and human 
methylome [15, 67]. In this study, DNA methylation was 
inversely correlated with gene expression. Targeted valida-
tion experiments supported this finding, providing some 
evidence for the biological significance of seizure-asso-
ciated DNA methylation changes. Both hyper- and hypo-
methylation events were detected with subsequent gene 
repression or activation. The calcium/calmodulin-depend-
ent protein kinase kinase 2, beta (Camkk2) was down-reg-
ulated in our chronic epileptic animals when compared to 
controls and showed intragenic hypermethylation. Camkk2 
is a key enzyme in calcium signaling, which mainly phos-
phorylates Camk1 and Camk4 as well as AMP-activated 
protein kinase (Ampk). It further seems to be involved in 
hippocampal activation of the transcription factor cAMP 
response element binding protein (Creb1) and downstream 
immediate early genes [62]. Camkk2 is highly expressed in 
the brain, and involved in long-term potentiation and hip-
pocampus-dependent memory formation [56], granule cell 
development [37] and cortical axon elongation [2]. Thus, 
altered expression of Camkk2 may contribute to seizure-
associated memory impairment. In contrast, the Il10rb was 
hypomethylation in the chronic epileptic PIlO cohort and 
this was consistent with increased gene expression. Il10rb 
belongs to the cytokine receptor family and is an essential 
accessory chain for the active Il-10 receptor complex. The 
localization of the Il-10 receptor in five major regions of 
the rat brain including hippocampus supports a central role 
in inflammation signaling [76]. Interestingly, the expres-
sion of Il-10 is elevated during the course of most major 
diseases in the CNS including Tle and promotes survival 
of neurons and all glial cells in the brain by blocking the 
effects of proapoptotic cytokines and promoting expression 
of cell survival signals [32, 71]. Therefore, overexpression 
of Il10rb in rat epilepsy could be a compensatory mecha-
nism to limit brain damage following seizures.
genome-wide profiling also clearly identified methyla-
tion changes that did not correspond with gene expression 
changes. Transcriptional regulation is dependent on several 
mechanisms that include chromatin remodeling, micro-
rNAs, histone modifications as well as transcription fac-
tor binding together with DNA methylation. Consistent 
with this, we identified differential gene expression for a 
number of epigenetic enzymes (Table 4) as well as bind-
ing motifs for key transcriptional activators (Nfkb, Kat2a, 
Zzz3, gtf2b, p300) and repressors (Nrsf, Suz12) overrep-
resented in our gene sets. Interestingly, some transcrip-
tion factors also function to regulate chromatin structure 
[3, 29, 46, 70]. Our analysis highlighted Prc2 interaction 
conferred by Suz12. Previous studies suggest that the Prc2 
complex may serve as a recruiting platform also for Dnmts, 
thereby linking two epigenetic repression systems [66, 75]. 
Our data do not support this interplay as downregulated 
genes with Suz12 response element did not show increased 
DNA methylation. This finding is in line with recent stud-
ies, where authors showed that trimethylation of histone 
3 lysine 27 (H3K27) and DNA methylation are mutually 
exclusive particularly at CgIs [11, 24]. Taken together, 
our in silico analysis of common transcription factor bind-
ing motifs supports a model of transcriptional regulation 
in chronic rat epilepsy, where gene activation is conferred 
by histone acetylation and gene suppression mediated by 
antagonistic effects of DNA and histone methylation.
In this study, DNA methylation provided a strong signal 
to separate chronic epileptic rats from healthy controls, but 
it remained unsolved, whether the presence of spontaneous 
seizures (epilepsy) led to altered methylation, or if altered 
methylation influenced seizures. To test the first hypothesis, 
we analyzed whether early administration of a high-fat, 
high-protein, low-carbohydrate ketogenic diet (KD) would 
partially rescue the seizure-associated and gene regulating 
DNA methylation changes in our rat Tle model. The KD 
is a clinically effective treatment in children with epilepsy 
and severe cognitive impairment, pharmacoresistant to con-
ventional and even newer anti-convulsant medications [54]. 
We show that KD administration in our epilepsy model par-
tially attenuated seizure burden, delayed disease progres-
sion and interfered with aberrant seizure-related genomic 
and locus specific alterations in DNA methylation and gene 
expression. How the ketogenic diet works to control or 
attenuate seizures remains poorly understood [13, 48]. The 
mechanisms proposed include metabolic changes (restrict-
ing glycolysis, increasing fatty acid oxidation, mitochon-
drial respiration and ATP synthesis), increased gABAergic 
inhibition, modulation of oxidative stress and neuropro-
tection [63]. It is most likely that described mechanisms 
work complementary, and we suggest that direct or indirect 
induction of epigenetic changes may add to this complexity 
[23, 49, 68].
Consistent with our hypothesis that gene expression 
changes associated with the anti-seizure phenotype, we 
compared a differential gene list derived from a recent 
study involving also non-epileptic KD-treated control 
animals [10] with the rank of our PIlO + KD cohort. 
Comparison of data sets showed no correlation of gene 
expression patterns with diet, supporting the idea that 
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the anti-convulsive properties of the KD contribute to 
DNA methylation mediated gene expression changes in 
PIlO + KD. Future studies could determine whether 
DNA methylation affects seizures using known DNMT 
inhibitors. Since they have not been tested thoroughly this 
remains speculative. The proposed relationship between 
neuronal hypersynchronous activity and gene regulation 
mediated by epigenetic changes could also be explored 
beyond the present study design to address timing and sig-
nal transition from the acute to the chronic disease phase 
as well as cell-specificity of epigenetic events. We cannot 
exclude that regional differences in DNA methylation and 
gene expression in our study may have been masked in 
part using whole hippocampus. Prospective utilization of 
microdissected homogenous cell populations from specific 
hippocampal subfields will help to decipher where exactly 
seizure-related DNA methylation changes occur (e.g., glia 
or the neuronal subpopulations of pyramidal and granu-
lar cells), and which of the detected signals in the present 
study were only related to cell composition effects in the 
different samples.
In conclusion, the characterization of mechanisms 
underlying epigenetic changes in the chronic epileptic brain 
should lead to a better understanding of disease. We con-
sider that our genome-wide analyses provide a comprehen-
sive profile of DNA methylation mediated gene expression 
changes, and may help to identify new regulatory targets 
in epilepsy, which again could be addressed by novel treat-
ment strategies. By defining the principal events mediating 
epigenomic changes it is anticipated that novel approaches 
will be developed to inhibit, attenuate or reverse the per-
sistent deleterious consequences of seizures in the epileptic 
brain.
Acknowledgments We kindly thank T. Jungbauer and B. rings 
for their expert technical assistance. This work was supported by 
epigeNet (DFg Bl 421/3-1). Assam el-Osta is an NHMrC Senior 
research Fellow.
Conflict of interest All authors confirm that there is no conflict of 
interest in relation to this article.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution license which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. NCBI resource Coordinators (2013) Database resources of the 
National Center for Biotechnology Information. Nucleic Acids 
res 41:D8–D20
 2. Ageta-Ishihara N, Takemoto-Kimura S, Nonaka M, Adachi-
Morishima A, Suzuki K, Kamijo S, Fujii H, Mano T, Blaeser 
F, Chatila TA, Mizuno H, Hirano T, Tagawa Y, Okuno H, Bito 
H et al (2009) Control of cortical axon elongation by a gABA-
driven Ca2+/calmodulin-dependent protein kinase cascade. J 
Neurosci 29:13720–13729
 3. Allis CD, Jenuwein T, reinberg D, Caparros M-l (eds) (2007) 
epigenetics. Cold Spring Harbor laboratory Press Cold Spring 
Harbor, New York
 4. Becker AJ, Chen J, Zien A, Sochivko D, Normann S, Schramm J, 
elger Ce, Wiestler OD, Blumcke I et al (2003) Correlated stage- 
and subfield-associated hippocampal gene expression patterns in 
experimental and human temporal lobe epilepsy. eur J Neurosci 
18:2792–2802
 5. Becker AJ, Pitsch J, Sochivko D, Opitz T, Staniek M, Chen CC, 
Campbell KP, Schoch S, Yaari Y, Beck H et al (2008) Transcrip-
tional upregulation of Cav3.2 mediates epileptogenesis in the 
pilocarpine model of epilepsy. J Neurosci 28:13341–13353
 6. Benjamini Y, Hochberg Y (1995) Controlling the false discov-
ery rate: a practical and powerful approach to multiple testing. J 
royal Stat Soc Ser B (Methodol) 57:289–300
 7. Blumcke I, Coras r, Miyata H, Ozkara C et al (2012) Defining 
clinico-neuropathological subtypes of mesial temporal lobe epi-
lepsy with hippocampal sclerosis. Brain Pathol 22:402–411
 8. Blumcke I, Pauli e, Clusmann H, Schramm J, Becker A, elger 
C, Merschhemke M, Meencke HJ, lehmann T, von Deimling A, 
Scheiwe C, Zentner J, Volk B, romstock J, Stefan H, Hildebrandt 
M et al (2007) A new clinico-pathological classification system 
for mesial temporal sclerosis. Acta Neuropathol 113:235–244
 9. Blumcke I, Thom M, Aronica e, Armstrong DD, Bartolomei F, 
Bernasconi A, Bernasconi N, Bien Cg, Cendes F, Coras r, Cross 
JH, Jacques TS, Kahane P, Mathern gW, Miyata H, Moshe Sl, 
Oz B, Ozkara C, Perucca e, Sisodiya S, Wiebe S, Spreafico r 
et al (2013) International consensus classification of hippocam-
pal sclerosis in temporal lobe epilepsy: a task force report 
from the IlAe Commission on diagnostic methods. epilepsia 
54(7):1315–1329
 10. Bough KJ, Wetherington J, Hassel B, Pare JF, gawryluk JW, 
greene Jg, Shaw r, Smith Y, geiger JD, Dingledine rJ et al 
(2006) Mitochondrial biogenesis in the anticonvulsant mecha-
nism of the ketogenic diet. Ann Neurol 60:223–235
 11. Brinkman AB, gu H, Bartels SJ, Zhang Y, Matarese F, Simmer 
F, Marks H, Bock C, gnirke A, Meissner A, Stunnenberg Hg 
et al (2012) Sequential ChIP-bisulfite sequencing enables direct 
genome-scale investigation of chromatin and DNA methylation 
cross-talk. genome res 22:1128–1138
 12. Brinkman AB, Simmer F, Ma K, Kaan A, Zhu J, Stunnenberg 
Hg et al (2010) Whole-genome DNA methylation profiling using 
MethylCap-seq. Methods 52:232–236
 13. Cross JH (2013) New research with diets and epilepsy. J Child 
Neurol 28:970–974
 14. Crowe Sl, Tsukerman S, gale K, Jorgensen TJ, Kondratyev 
AD et al (2011) Phosphorylation of histone H2A.X as an early 
marker of neuronal endangerment following seizures in the adult 
rat brain. J Neurosci 31:7648–7656
 15. Deaton AM, Webb S, Kerr Ar, Illingworth rS, guy J, Andrews 
r, Bird A et al (2011) Cell type-specific DNA methylation at 
intragenic Cpg islands in the immune system. genome res 
21:1074–1086
 16. elliott rC, Miles MF, lowenstein DH (2003) Overlapping micro-
array profiles of dentate gyrus gene expression during develop-
ment- and epilepsy-associated neurogenesis and axon outgrowth. 
J Neurosci 23:2218–2227
 17. eNCODe Project Consortium, Bernstein Be, Birney e, Dun-
ham I, green eD, gunter C, Snyder M et al (2012) An integrated 
encyclopedia of DNA elements in the human genome. Nature 
489:57–74
 18. Feil r, Fraga MF (2012) epigenetics and the environment: 
emerging patterns and implications. Nat rev genet 13:97–109
755Acta Neuropathol (2013) 126:741–756 
1 3
 19. Feng J, Zhou Y, Campbell Sl, le T, li e, Sweatt JD, Silva AJ, 
Fan g et al (2010) Dnmt1 and Dnmt3a maintain DNA methyla-
tion and regulate synaptic function in adult forebrain neurons. 
Nat Neurosci 13:423–430
 20. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai lH et al 
(2007) recovery of learning and memory is associated with chro-
matin remodelling. Nature 447:178–182
 21. garriga-Canut M, Schoenike B, Qazi r, Bergendahl K, Daley 
TJ, Pfender rM, Morrison JF, Ockuly J, Stafstrom C, Sutula T, 
roopra A et al (2006) 2-Deoxy-d-glucose reduces epilepsy pro-
gression by NrSF-CtBP-dependent metabolic regulation of chro-
matin structure. Nat Neurosci 9:1382–1387
 22. gorter JA, van Vliet eA, Aronica e, Breit T, rauwerda H, lopes 
da Silva FH, Wadman WJ et al (2006) Potential new antiepilepto-
genic targets indicated by microarray analysis in a rat model for 
temporal lobe epilepsy. J Neurosci 26:11083–11110
 23. greene rW (2011) Adenosine: front and center in linking 
nutrition and metabolism to neuronal activity. J Clin Invest 
121:2548–2550
 24. Hagarman JA, Motley MP, Kristjansdottir K, Soloway PD (2013) 
Coordinate regulation of DNA methylation and H3K27me3 in 
mouse embryonic stem cells. PloS One 8:e53880
 25. Harikrishnan KN, Bayles r, Ciccotosto gD, Maxwell S, Cap-
pai r, Pelka gJ, Tam PP, Christodoulou J, el-Osta A et al 
(2010) Alleviating transcriptional inhibition of the norepineph-
rine slc6a2 transporter gene in depolarized neurons. J Neurosci 
30:1494–1501
 26. Hendriksen H, Datson NA, ghijsen We, van Vliet eA, da Silva 
FH, gorter JA, Vreugdenhil e et al (2001) Altered hippocampal 
gene expression prior to the onset of spontaneous seizures in the 
rat post-status epilepticus model. eur J Neurosci 14:1475–1484
 27. da Huang W, Sherman BT, lempicki rA (2009) Systematic and 
integrative analysis of large gene lists using DAVID bioinformat-
ics resources. Nat Protoc 4:44–57
 28. Huang Y, Doherty JJ, Dingledine r (2002) Altered histone acety-
lation at glutamate receptor 2 and brain-derived neurotrophic fac-
tor genes is an early event triggered by status epilepticus. J Neu-
rosci 22:8422–8428
 29. Huang Y, Myers SJ, Dingledine r (1999) Transcriptional repres-
sion by reST: recruitment of Sin3A and histone deacetylase to 
neuronal genes. Nat Neurosci 2:867–872
 30. Jia YH, Zhu X, li SY, Ni JH, Jia HT et al (2006) Kainate expo-
sure suppresses activation of glur2 subunit promoter in primary 
cultured cerebral cortical neurons through induction of re1-
silencing transcription factor. Neurosci lett 403:103–108
 31. Jimenez-Mateos eM, engel T, Merino-Serrais P, McKiernan 
rC, Tanaka K, Mouri g, Sano T, O’Tuathaigh C, Waddington 
Jl, Prenter S, Delanty N, Farrell MA, O’Brien DF, Conroy rM, 
Stallings rl, Defelipe J, Henshall DC et al (2012) Silencing 
microrNA-134 produces neuroprotective and prolonged seizure-
suppressive effects. Nat Med 18:1087–1094
 32. Kan AA, de Jager W, de Wit M, Heijnen C, van Zuiden M, Fer-
rier C, van rijen P, gosselaar P, Hessel e, van Nieuwenhuizen O, 
de graan PN et al (2012) Protein expression profiling of inflam-
matory mediators in human temporal lobe epilepsy reveals co-
activation of multiple chemokines and cytokines. J Neuroinflamm 
9:207
 33. Kobow K, Auvin S, Jensen F, loscher W, Mody I, Potschka H, 
Prince D, Sierra A, Simonato M, Pitkanen A, Nehlig A, rho JM 
et al (2012) Finding a better drug for epilepsy: antiepileptogen-
esis targets. epilepsia 53:1868–1876
 34. Kobow K, Blumcke I (2011) The methylation hypothesis: do epi-
genetic chromatin modifications play a role in epileptogenesis? 
epilepsia 52(Suppl 4):15–19
 35. Kobow K, Blumcke I (2012) The emerging role of DNA methyla-
tion in epileptogenesis. epilepsia 53(Suppl 9):11–20
 36. Kobow K, Jeske I, Hildebrandt M, Hauke J, Hahnen e, Buslei r, 
Buchfelder M, Weigel D, Stefan H, Kasper B, Pauli e, Blumcke 
I et al (2009) Increased reelin promoter methylation is associated 
with granule cell dispersion in human temporal lobe epilepsy. J 
Neuropathol exp Neurol 68:356–364
 37. Kokubo M, Nishio M, ribar TJ, Anderson KA, West Ae, Means 
Ar et al (2009) BDNF-mediated cerebellar granule cell develop-
ment is impaired in mice null for CaMKK2 or CaMKIV. J Neuro-
sci 29:8901–8913
 38. Kossoff eH, Hartman Al (2012) Ketogenic diets: new advances 
for metabolism-based therapies. Curr Opin Neurol 25:173–178
 39. Krzywinski M, Schein J, Birol I, Connors J, gascoyne r, Hors-
man D, Jones SJ, Marra MA et al (2009) Circos: an information 
aesthetic for comparative genomics. genome res 19:1639–1645
 40. lemke Jr, riesch e, Scheurenbrand T, Schubach M, Wilhelm 
C, Steiner I, Hansen J, Courage C, gallati S, Burki S, Strozzi S, 
Simonetti Bg, grunt S, Steinlin M, Alber M, Wolff M, Klopstock 
T, Prott eC, lorenz r, Spaich C, rona S, lakshminarasimhan 
M, Kroll J, Dorn T, Kramer g, Synofzik M, Becker F, Weber Yg, 
lerche H, Bohm D, Biskup S et al (2012) Targeted next genera-
tion sequencing as a diagnostic tool in epileptic disorders. epilep-
sia 53:1387–1398
 41. levenson JM, roth Tl, lubin FD, Miller CA, Huang IC, Desai 
P, Malone lM, Sweatt JD et al (2006) evidence that DNA (cyto-
sine-5) methyltransferase regulates synaptic plasticity in the hip-
pocampus. J Biol Chem 281:15763–15773
 42. levenson JM, Sweatt JD (2005) epigenetic mechanisms in mem-
ory formation. Nat rev Neurosci 6:108–118
 43. li H, Durbin r (2009) Fast and accurate short read alignment 
with Burrows-Wheeler transform. Bioinformatics 25:1754–1760
 44. liu M, Sheng Z, Cai l, Zhao K, Tian Y, Fei J et al (2012) Neu-
ronal conditional knockout of NrSF decreases vulnerability to 
seizures induced by pentylenetetrazol in mice. Acta Biochim Bio-
phys Sin 44:476–482
 45. lukasiuk K, Dabrowski M, Adach A, Pitkanen A et al (2006) 
epileptogenesis-related genes revisited. Prog Brain res 158: 
223–241
 46. Margueron r, reinberg D (2011) The Polycomb complex PrC2 
and its mark in life. Nature 469:343–349
 47. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, Fan g, 
Sun Ye et al (2003) DNA methylation-related chromatin remod-
eling in activity-dependent BDNF gene regulation. Science 
302:890–893
 48. Masino SA, Kawamura M Jr, ruskin DN, geiger JD, Boison 
D et al (2012) Purines and neuronal excitability: links to the 
ketogenic diet. epilepsy res 100:229–238
 49. Masino SA, li T, Theofilas P, Sandau US, ruskin DN, Fredholm 
BB, geiger JD, Aronica e, Boison D et al (2011) A ketogenic 
diet suppresses seizures in mice through adenosine A receptors. J 
Clin Invest 121:2679–2683
 50. Masino SA, rho JM (2012) Mechanisms of ketogenic diet action. 
In: Noebels Jl, Avoli M, rogawski MA, Olsen rW, Delgado-
escueta AV (eds) Jasper’s basic mechanisms of the epilepsies 
(contemporary neurology series). Oxford University Press, 
Oxford, pp 1003–1024
 51. McClelland S, Flynn C, Dubé C, richichi C, Zha Q, ghestem A, 
esclapez M, Bernard C, Baram TZ et al (2011) Neuron-restric-
tive silencer factor-mediated hyperpolarization-activated cyclic 
nucleotide gated channelopathy in experimental temporal lobe 
epilepsy. Ann Neurol 70:454–464
 52. Mikkelsen TS, Ku M, Jaffe DB, Issac B, lieberman e, gian-
noukos g, Alvarez P, Brockman W, Kim TK, Koche rP, lee W, 
Mendenhall e, O’Donovan A, Presser A, russ C, Xie X, Meiss-
ner A, Wernig M, Jaenisch r, Nusbaum C, lander eS, Bernstein 
Be et al (2007) genome-wide maps of chromatin state in pluri-
potent and lineage-committed cells. Nature 448:553–560
756 Acta Neuropathol (2013) 126:741–756
1 3
 53. Miller-Delaney SF, Das S, Sano T, Jimenez-Mateos eM, Bryan 
K, Buckley Pg, Stallings rl, Henshall DC et al (2012) Differen-
tial DNA methylation patterns define status epilepticus and epi-
leptic tolerance. J Neurosci 32:1577–1588
 54. Neal eg, Chaffe H, Schwartz rH, lawson MS, edwards N, 
Fitzsimmons g, Whitney A, Cross JH et al (2008) The ketogenic 
diet for the treatment of childhood epilepsy: a randomised con-
trolled trial. lancet Neurol 7:500–506
 55. Okano M, Bell DW, Haber DA, li e et al (1999) DNA methyl-
transferases Dnmt3a and Dnmt3b are essential for de novo meth-
ylation and mammalian development. Cell 99:247–257
 56. Peters M, Mizuno K, ris l, Angelo M, godaux e, giese KP et al 
(2003) loss of Ca2+/calmodulin kinase kinase beta affects the 
formation of some, but not all, types of hippocampus-dependent 
long-term memory. J Neurosci 23:9752–9760
 57. Pirola l, Balcerczyk A, Tothill rW, Haviv I, Kaspi A, lunke S, 
Ziemann M, Karagiannis T, Tonna S, Kowalczyk A, Beresford-
Smith B, Macintyre g, Kelong M, Hongyu Z, Zhu J, el-Osta A 
et al (2011) genome-wide analysis distinguishes hyperglyce-
mia regulated epigenetic signatures of primary vascular cells. 
genome res 21:1601–1615
 58. Pitkanen A, lukasiuk K (2011) Mechanisms of epileptogenesis 
and potential treatment targets. lancet Neurol 10:173–186
 59. Quinlan Ar, Hall IM (2010) BeDTools: a flexible suite of utili-
ties for comparing genomic features. Bioinformatics 26:841–842
 60. Qureshi IA, Mehler MF (2010) epigenetic mechanisms underly-
ing human epileptic disorders and the process of epileptogenesis. 
Neurobiol Dis 39:53–60
 61. racine rJ (1972) Modification of seizure activity by electrical 
stimulation. II. Motor seizure. electroencephalogr Clin Neuro-
physiol 32:281–294
 62. racioppi l, Means Ar (2012) Calcium/calmodulin-dependent 
protein kinase kinase 2: roles in signaling and pathophysiology. J 
Biol Chem 287:31658–31665
 63. rho JM, Sankar r (2008) The ketogenic diet in a pill: is this pos-
sible? epilepsia 49(Suppl 8):127–133
 64. robinson MD, McCarthy DJ, Smyth gK (2010) edger: a bio-
conductor package for differential expression analysis of digital 
gene expression data. Bioinformatics 26:139–140
 65. robinson MD, Oshlack A (2010) A scaling normalization method 
for differential expression analysis of rNA-seq data. genome 
Biol 11:r25
 66. rush M, Appanah r, lee S, lam ll, goyal P, lorincz MC et al 
(2009) Targeting of eZH2 to a defined genomic site is sufficient 
for recruitment of Dnmt3a but not de novo DNA methylation. 
epigenetics 4:404–414
 67. Sati S, Tanwar VS, Kumar KA, Patowary A, Jain V, ghosh S, 
Ahmad S, Singh M, reddy SU, Chandak gr, raghunath M, 
Sivasubbu S, Chakraborty K, Scaria V, Sengupta S et al (2012) 
High resolution methylome map of rat indicates role of intragenic 
DNA methylation in identification of coding region. PloS One 
7:e31621
 68. Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, le 
Moan N, grueter CA, lim H, Saunders lr, Stevens rD, New-
gard CB, Farese rV Jr, de Cabo r, Ulrich S, Akassoglou K, 
Verdin e et al (2013) Suppression of oxidative stress by beta-
hydroxybutyrate, an endogenous histone deacetylase inhibitor. 
Science 339:211–214
 69. Sng JC, Taniura H, Yoneda Y (2006) Histone modifications in 
kainate-induced status epilepticus. eur J Neurosci 23:1269–1282
 70. Sterner De, Berger Sl (2000) Acetylation of histones and tran-
scription-related factors. Microbiol Mol Biol rev 64:435–459
 71. Strle K, Zhou JH, Shen WH, Broussard Sr, Johnson rW, Fre-
und gg, Dantzer r, Kelley KW et al (2001) Interleukin-10 in the 
brain. Crit rev Immunol 21:427–449
 72. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, ebert Bl, 
gillette MA, Paulovich A, Pomeroy Sl, golub Tr, lander eS, 
Mesirov JP et al (2005) gene set enrichment analysis: a knowl-
edge-based approach for interpreting genome-wide expression 
profiles. Proc Natl Acad Sci USA 102:15545–15550
 73. Tsankova NM, Kumar A, Nestler eJ (2004) Histone modifica-
tions at gene promoter regions in rat hippocampus after acute and 
chronic electroconvulsive seizures. J Neurosci 24:5603–5610
 74. Vezzani A, French J, Bartfai T, Baram TZ et al (2011) The role of 
inflammation in epilepsy. Nat rev Neurol 7:31–40
 75. Vire e, Brenner C, Deplus r, Blanchon l, Fraga M, Didelot C, 
Morey l, Van eynde A, Bernard D, Vanderwinden J-M, Bollen 
M, esteller M, Di Croce l, de launoit Y, Fuks F et al (2006) The 
Polycomb group protein eZH2 directly controls DNA methyla-
tion. Nature 439:871–874
 76. Ward H, Vigues S, Poole S, Bristow AF et al (2001) The rat inter-
leukin 10 receptor: cloning and sequencing of cDNA coding for 
the alpha-chain protein sequence, and demonstration by western 
blotting of expression in the rat brain. Cytokine 15:237–240
 77. Weber M, Hellmann I, Stadler MB, ramos l, Paabo S, rebhan 
M, Schubeler D et al (2007) Distribution, silencing potential and 
evolutionary impact of promoter DNA methylation in the human 
genome. Nat genet 39:457–466
 78. Zhang Y, liu T, Meyer CA, eeckhoute J, Johnson DS, Bern-
stein Be, Nusbaum C, Myers rM, Brown M, li W, liu XS et al 
(2008) Model-based analysis of ChIP-Seq (MACS). genome 
Biol 9:r137
 79. Zhu Q, Wang l, Zhang Y, Zhao FH, luo J, Xiao Z, Chen gJ, 
Wang XF et al (2011) Increased expression of DNA methyltrans-
ferase 1 and 3a in human temporal lobe epilepsy. J Mol Neurosci 
46:420–426
